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Abstract 
 
Background 
Increased resting heart rate is a risk factor for cardiovascular mortality and morbidity. 
Mineralocorticoid receptor antagonists (MRAs) have been shown to improve cardiac 
sympathetic nerve activity, reduce heart rate and attenuate left ventricular remodelling. 
Whether or not the beneficial effects of MRA are affected by heart rate in heart failure 
patients with reduced ejection fraction (HFREF) is unclear.   
 
Methods 
We undertook a secondary analysis of data from the Eplerenone in Mild Patients 
Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) study to assess if 
clinical outcomes, as well as the efficacy of eplerenone, varied according to heart rate at 
baseline. 
 
Results 
High resting heart rate of 80bpm and above predisposed patients to greater risk of all 
outcomes in the trial, regardless of treatment allocation. The beneficial effects of eplerenone 
were observed across all categories of heart rate. Eplerenone reduced the risk of primary 
endpoint, the composite of cardiovascular death and hospitalisation for heart failure, by 30% 
(aHR, 0.70; 95% CI, 0.54 to 0.91) in subjects with heart rate ≥80bpm, and by 48% (aHR, 
0.52; 95% CI, 0.33 to 0.81) in subjects with heart rate ≤60bpm. Eplerenone also reduced the 
risks of hospitalisation for heart failure, cardiovascular deaths and all-cause deaths 
independently of baseline heart rate. 
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Conclusions 
Baseline heart rate appears to be an important predictor of major clinical outcome events in 
patients with HFREF, as has been previously reported. The benefits of eplerenone were 
preserved across all categories of baseline heart rate, without observed heterogeneity in the 
responses.   
 
 
Key words: ClinicalTrials.gov identifier: NCT00232180; heart rate; aldosterone antagonists; 
aldosterone; heart failure  
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Introduction 
Elevated resting heart rate is an established risk factor for cardiovascular mortality 
and morbidity in people with cardiovascular disease [1]. The magnitude of autonomic 
dysfunction is partly reflected by heart rate [2], and increased heart rate accelerates the 
progression of coronary atherosclerosis, as well as predisposes to myocardial ischaemia, 
ventricular arrhythmias and left ventricular dysfunction [3,4].  
Lower resting heart rate was associated with better prognosis for patients with heart 
failure with reduced ejection fraction (HFREF) in sinus rhythm, regardless of beta-blocker 
(BB) use in the Candesartan in Heart Failure: Assessment of Reduction in Mortality and 
morbidity (CHARM) program [5]. In a meta-analysis of randomised controlled trials 
comparing BB and placebo in patients with HFREF [6], higher heart rate was associated with 
a higher risk of all-cause mortality for patients in sinus rhythm [adjusted hazards ratio (aHR), 
1.11 per 10 beats per min (bpm); 95% confidence interval (CI), 1.07 to 1.15], but not atrial 
fibrillation (AF) (aHR, 1.03 per 10 bpm; 95% CI, 0.97 to 1.08). Furthermore, patients with 
the highest heart rates at baseline had the greatest reduction in outcomes after being treated 
with ivabradine in the Systolic Heart failure treatment with the If inhibitor ivabradine Trial 
(SHIFT) [7].  
Aldosterone is known to augment the sympathetic activity of catecholamines by 
attenuating their uptake by myocardial tissues, leading to autonomic dysfunction [8]. It also 
blunts the baroreceptor response by decreasing parasympathetic action via stimulation of 
Na+/K+/ATPase [9]. It is for these reasons that the mineralocorticoid receptor antagonists 
(MRAs) improve cardiac autonomic function, reduce heart rate and attenuate left ventricular 
remodelling [10-12]. While the clinical benefits of MRAs are mainly driven by 
mineralocorticoid receptor antagonism, it is not known whether these effects vary according 
to heart rate. This is a relevant question in view of the interaction of MRAs with the 
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sympathetic nervous system and because heart rate reflects sympathetic activity. 
Accordingly, we sought to determine the efficacy of the MRA eplerenone according to 
baseline heart rate in the Eplerenone in Mild Patients Hospitalization and Survival Study in 
Heart Failure (EMPHASIS-HF) study.  
 
Methods 
Study design and patient population 
The patients involved in EMPHASIS-HF have been described in detail previously 
[13,14]. In brief, patients were eligible for enrolment if they: i) had New York Heart 
Association (NYHA) class II symptoms; ii) were >55 years of age;  iii) had an ejection 
fraction of no more than 30% (or 30%–35% if QRS duration >130 ms); iv) were receiving 
standard background heart failure therapy comprising angiotensin-converting enzyme (ACE) 
inhibitors, angiotensin receptor blockers (ARB) (or both), and BB at recommended or 
maximal tolerated doses; and v) had been hospitalised for cardiovascular reasons within the 
past six months, or had a plasma B-type natriuretic peptide (BNP) of at least 250 pg/mL or N 
terminal proBNP (NT-proBNP) ≥500 pg/mL for males and ≥750 pg/mL for females within 
15 days prior to randomisation. Investigators were encouraged to up-titrate patients to the 
highest stable doses of these therapies before randomisation. Key exclusion criteria included 
an indication for MRA treatment according to current heart failure guidelines, need for 
adjunctive potassium-sparing diuretic therapy, serum potassium >5.0 mmol/L within 24 
hours prior to randomisation, estimated glomerular filtration rate <30 mL/min/1.73 m2 within 
24 hours prior to randomisation, and any other significant co-morbid condition. 
 Patients were randomised to receive either eplerenone (up to 50mg daily) or placebo, 
in addition to recommended therapy. Patients were reviewed four weeks after randomisation 
and then every four months during follow-up. The primary outcome was the composite of 
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death from cardiovascular causes or hospitalisation for heart failure. An independent 
Endpoint Events Committee adjudicated all the study endpoint events. The trial was stopped 
prematurely due to evidence of overwhelming benefit with eplerenone, after a median follow-
up period of 21 months. 
In the present analysis, we undertook a post hoc assessment of clinical outcomes 
according to heart rate at baseline, as well as of the efficacy of eplerenone according to 
baseline heart rate categories. Event rates for the primary composite outcome and its 
components were calculated according to study treatment assignment (eplerenone or placebo) 
and baseline heart rate was categorised a priori into the groups <60, 60-69, 70-79 and 80+ 
bpm. The cut-points for these groups corresponded closely to those for quartiles of the heart 
rate distribution in the sample (62, 71, 82 bpm). The consequent event rates and 95% CI were 
based on the Poisson distribution, adjusted for age, sex, race, systolic blood pressure, body 
mass index, left ventricular ejection fraction, serum creatinine, cause of heart failure, duration 
of heart failure, diabetes mellitus, AF, hypertension, prior hospitalisation for heart failure, 
stroke, implantable cardioverter-defibrillator/cardiac-resynchronisation therapy and 
medications (ACE inhibitors/ARBs, BBs, BBs dose, non-dihydropyridine calcium channel 
blockers, digoxin and antiarrhythmic agents). Efficacy analyses were performed using a 
multivariable Cox proportional hazards models, adjusted for the same list of covariates stated 
above. All p-values were two sided. Analyses were performed using Stata Version 15 
(StataCorp 2015).  
 
Results 
Baseline characteristics according to heart rate 
Of the total of 2,737 patients in the EMPHASIS-HF, data from 2,736 patients were 
available for the analysis. Baseline characteristics of patients according to heart rate are 
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summarised in Table 1. At baseline, a total of 844 (31%) had history of AF. Patients with 
higher baseline heart rate were younger, and more likely to have elevated diastolic blood 
pressure, non-ischaemic aetiology of heart failure, AF or flutter, diabetes, prior 
hospitalisation for heart failure, and be prescribed diuretics and digoxin. In contrast, patients 
with lower heart rate were more likely to be ex-smokers, have an ischaemic origin of heart 
failure, coronary artery disease, a history of undergoing percutaneous coronary interventions 
and coronary artery bypass grafting, implantable cardiac defibrillator, and be prescribed BB, 
non-dihydropyridine calcium channel blockers, antiarrhythmic agents, antithrombotics and 
lipid lowering drugs. More than 80% of the patients were prescribed ACE inhibitors/ARB 
and BB. 
 
Association between baseline heart rate and clinical outcomes 
Results pertaining to the primary endpoint (composite of cardiovascular death or 
hospitalisation for heart failure), cardiovascular death alone, hospitalisation for heart failure 
alone and all-cause mortality according to baseline resting heart rate are summarised in Table 
2 and Figure 1. Compared to patients with a baseline heart rate of 60-69bpm, those with 
baseline heart rate of 80+bpm experienced a greater rate of the primary endpoint (17.2 per 
100 patient-year versus 10.5 per 100 patient-year, adjusted hazard ratio (aHR) 1.61, 95% CI 
1.31 to 1.99). The rates of cardiovascular death, hospitalisation for heart failure and all-cause 
mortality were also significantly higher.  
Figure 2 depicts adjusted event rates for each outcome according to baseline heart rate 
categories and randomised group. Lower event rates were observed in eplerenone compared 
with placebo in each heart rate category, with similar absolute differences in event rates 
across the categories.  
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The beneficial effects of eplerenone were preserved across all heart rate categories 
(Figure 3). The reduction in the primary endpoint and hospitalisation for heart failure were 
consistently above 30% across all heart rates, favouring eplerenone (Figure 3). Eplerenone 
reduced the risk of primary endpoint by 30% (aHR, 0.70; 95% CI, 0.54 to 0.91) among 
patients with baseline heart rate ≥80bpm and by 48% (aHR, 0.52; 95% CI, 0.33 to 0.81) 
among patients with baseline heart rate ≤60bpm. Similar results were observed in 
hospitalisation for heart failure. Eplerenone also reduced the risks of cardiovascular and all-
cause deaths risks in a similar fashion, but with broad confidence interval bands that crossed 
the null value in subgroups with heart rate 70bpm and above. However, there was no 
evidence of interaction between eplerenone and heart rate (trend P-value = 0.08 to 0.73). 
Also, AF was not found to modify the effect of eplerenone (trend P-value = 0.59). 
A total of 61 (2%) patients were excluded from the fully adjusted models due to 
missing data on risk factors. Subsequent sensitivity analyses using multiple imputation with 
chained equations did not change the conclusions. Further exploratory analysis treating heart 
rate as a continuous variable was carried out but did not add to or alter any conclusions. 
 
Discussion 
To the best of our knowledge, this is the first study to examine the influence of heart 
rate on subsequent cardiovascular events in a trial using a MRA in patients with heart failure. 
We found that a high resting heart rate of 80+bpm predisposed patients with HFREF to a 
greater risk of primary endpoint, cardiovascular deaths, hospitalisation for heart failure and 
all-cause death, regardless of treatment allocation. The beneficial effects of eplerenone were 
preserved across all categories of baseline heart rate.  
Notably, patients with higher baseline heart rates displayed distinct clinical 
characteristics compared to those with lower heart rates, with a trend towards lower use of 
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BBs and higher prevalence of AF or flutter, diabetes and previous hospitalisation for heart 
failure. Such discrepancies may explain the increased heart rate and possible decrease in the 
effect of eplerenone on mortality.  
Higher heart rate may reflect a compensatory mechanism for the loss of atrial 
contribution to cardiac output [15,16]. Autonomic dysfunction in heart failure, characterised 
by decreased tonic and reflex vagal heart rate modulation and increased heart rate, venous 
plasma norepinephrine and cardiac norepinephrine stores, has been associated with greater 
mortality [17]. Higher heart rate is also associated with increased energy expenditure, 
reduced myocardial oxygen delivery because of shorter diastole, and loss of the positive 
force-frequency relationship (Bowditch effect).[18] Over-activity of the sympathetic nervous 
system in heart failure, which is reflected by heart rate, has direct toxic effects on the cardiac 
myocytes, facilitates the development of ventricular arrhythmias and alteration of the beta-
adrenoceptor function [19].  
Accumulated evidence from the SHIFT, CHARM, and Efficacy of Vasopressin 
Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trials support 
heart rate being an independent predictor of mortality and cardiovascular outcomes, and also 
highlight the importance of a heart rate reduction strategy for improvement of clinical 
outcomes in patients with HFREF [5,20,21]. A resting heart rate of >76 bpm at any time 
during follow-up was associated with increased risk of cardiovascular death or hospitalisation 
for HF in the SHIFT and CHARM studies [7,22]. However, these findings do not apply to all 
patients with HFREF, as some studies have showed paradoxical findings of lower heart rate 
being associated with higher mortality in heart failure patients with concomitant AF, and to 
date, the mechanistic explanation for this interaction is less well established [5,23,24]. 
Although ivabradine does not reduce heart rate and BBs do not improve outcomes in patients 
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with HFREF and AF, treatment with MRAs has been demonstrated to reduce both heart rate 
and major cardiovascular outcomes in this subgroup of patients [12,25].  
Despite this, recent data from prospective observational studies suggest that MRAs 
remained under-prescribed and frequently discontinued among eligible patients with 
HFREF.[26-28] Only 40% to 60% of the patients in the BIOlogy Study to TAilored 
Treatment in Chronic Heart Failure (BIOSTAT-CHF) and Swedish Heart Failure Registry 
were prescribed a MRA [26,28]. In these studies, higher heart rate, lower use of BBs, history 
of diabetes, AF, hypertension, stroke/transient ischaemic attack, smoking, previous 
percutaneous coronary revascularisation, anaemia and the use of loop diuretics were 
associated with non-prescribing and under-dosing of MRAs among patients with HFREF. 
The observed association between heart rate and use of MRAs in these studies is likely to be 
confounded. 
The use of MRAs in HFREF has been shown to be cost-effective and has a significant 
impact on mortality and hospitalisation rates [29-32]. What is clear from our analysis is that 
the beneficial effects of eplerenone are preserved regardless of heart rate and higher heart rate 
is detrimental to patients with HFREF. These findings highlight the importance of optimising 
use of MRAs in eligible patients with HFREF.  
 
 Limitations 
There are a number of limitations to our post hoc analysis. First, analysis was 
confined to that of heart rate at baseline only; post-randomisation heart rates were not 
measured. In addition, we relied on investigator-reported baseline heart rate, which may not 
have been measured in a standardised manner, and estimation of the ventricular rate in 
patients with AF may also have been less reliable than in patients in sinus rhythm. However, 
previous analyses examining the relationship between heart rate and pharmacological 
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intervention in HFREF trials were also limited to baseline heart rate measured by 
investigators.[5,6,33] As with all subgroup analyses, there was less precision in the results for 
groups defined by baseline heart rate, reflected by wide 95% CIs. Furthermore, we 
acknowledge that our post hoc analyses were not pre-specified. Nonetheless, a dose-response 
effect was clear, the findings are of clinical relevance and they accord with those of other 
studies. 
 
Conclusions 
Baseline heart rate is a predictor of major clinical outcome events in patients with 
HFREF, as has been previously reported. The cardiovascular benefits of eplerenone in this 
patient population are preserved across all ranges of baseline heart rate.   
 
Acknowledgement 
The late Professor Henry Krum made substantial contributions to the study. 
 
Sources of Funding 
The EMPHASIS-HF Study was sponsored by Pfizer. 
 
Conflicts of Interest 
Drs Pitt, McMurray, Swedberg, van Veldhuisen, Pocock, and Zannad were members of the 
EMPHASIS-HF Writing Committee and report having received fees and travel support in the 
past from the study sponsor, Pfizer Inc, for participation in and traveling to meetings of the 
committee. Dr Vincent is currently employed by Pfizer and own stock in Pfizer Inc, the 
makers of eplerenone. Dr Pitt reports receiving fees for serving on the board of Novartis, 
consulting fees from Takeda, AstraZeneca, Boehringer Ingelheim, GE Healthcare, Relypsa, 
Page 12 of 24 
 
BG Medicine, Nile Therapeutics, Merck, Forest Laboratories, and Novartis, grant support 
from Forest Laboratories and Novartis, and stock options from Relypsa, BG Medicine, Nile 
Therapeutics, and Aurasenc and that his institution receives grant support from Forest 
Laboratories on his behalf and he and his institution receive grant support from Bayer. Dr 
Swedberg has received research support from Pfizer, Amgen, Novartis, and Servier. Dr 
Pocock reports receiving consulting fees from Servier, Amgen, AstraZeneca, and Novartis 
and that his institution receives grants from Servier and AstraZeneca on his behalf. Dr 
Zannad reports receiving fees for serving on the board of Boston Scientific, consulting fees 
from Novartis, Takeda, AstraZeneca, Boehringer Ingelheim, GE Healthcare, Relypsa, 
Servier, Boston Scientific, Bayer, Johnson & Johnson, and Resmed, and speaker’s fees from 
Pfizer and AstraZeneca and that his institution receives grant support from BG Medicine and 
Roche Diagnostics on his behalf. Dr Liew reports receiving grants and honoraria from 
Abbvie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Novartis, 
Pfizer, Sanofi and Shire. All other authors have reported that they have no relationships 
relevant to the contents of this paper to disclose. 
 
References 
 
1. Custodis F, Reil J-C, Laufs U, Böhm M (2013) Heart rate: A global target for 
cardiovascular disease and therapy along the cardiovascular disease continuum. J Cardiol 
62:183–187 
2. Komajda M (2015 ) Heart rate in chronic heart failure: an overlooked risk factor. Eur Heart 
J 36:648–649 
3. Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Sendon JLL, Steg PG, Tardif J-C, 
Tavazzi L, Tendera M, for the Heart Rate Working Group (2007) Resting heart rate in 
cardiovascular disease. J Am Coll Cardiol 50:823–830 
Page 13 of 24 
 
4. Custodis F, Schirmer SH, Baumhäkel M, Heusch G, Böhm M, Laufs U (2010) Vascular 
pathophysiology in response to increased heart rate. J Am Coll Cardiol 56:1973–1983 
5. Castagno D, Skali H, Takeuchi M, Swedberg K, Yusuf S, Granger CB, Michelson EL, 
Pfeffer MA, McMurray JJV, Solomon SD, for the CHARM Investigators (2012) 
Association of heart rate and outcomes in a broad spectrum of patients with chronic heart 
failure: Results from the CHARM (Candesartan in Heart Failure: Assessment of 
Reduction in Mortality and morbidity) Program. J Am Coll Cardiol 59:1785–1795 
6. Kotecha D, Flather MD, Altman DG, Holmes J, Rosano G, Wikstrand J, Packer M, Coats 
AJS, Manzano L, Böhm M, van Veldhuisen DJ, Andersson B, Wedel H, von Lueder TG, 
Rigby AS, Hjalmarson Å, Kjekshus J, Cleland JGF, on behalf of the Beta-Blockers in 
Heart Failure Collaborative Group (2017) Heart rate and rhythm and the benefit of beta-
blockers in patients with heart failure. J Am Coll Cardiol 69:2885–2896 
7. Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, 
Tavazzi L, on behalf of the SHIFT Investigators (2010) Heart rate as a risk factor in 
chronic heart failure (SHIFT): the association between heart rate and outcomes in a 
randomised placebo-controlled trial. Lancet 376:886–894 
8. Struthers AD (2002) Aldosterone: Cardiovascular assault. Am Heart J 144:S2-7 
9. Davies JI, Witham MD, Struthers AD (2005) Autonomic effects of spironolactone and MR 
blockers in heart failure. Heart Fail Rev 10:63–69 
10. Yee K, Struthers AD (1998) Aldosterone blunts the baroreflex response in man. Clin Sci 
(Lond) 95:687–692 
11. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M 
(2003) Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular 
remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 41:574–581 
Page 14 of 24 
 
12. MacFadyen RJ, Barr CS, Struthers AD (1997) Aldosterone blockade reduces vascular 
collagen turnover, improves heart rate variability and reduces early morning rise in heart 
rate in heart failure patients. Cardiovasc Res 35:30–34 
13. Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, 
Pocock S, Pitt B, for the EMPHASIS-HF Study Group (2011) Eplerenone in patients 
with systolic heart Failure and mild symptoms. N Engl J Med 364:11-21 
14. Zannad F, McMurray JJV, Drexler H, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, 
Vincent J, Pitt B (2010) Rationale and design of the Eplerenone in Mild Patients 
Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail 
12:617–622 
15. Rawles JM (1990) What is meant by a "controlled" ventricular rate in atrial fibrillation? 
Br Heart J 63:157-161 
16. Atwood JE, Myers J, Sullivan M, Forbes S, Friis R, Pewen W, Callaham P, Hall P, 
Froelicher V (1988) Maximal exercise testing and gas exchange in patients with chronic 
atrial fibrillation. J Am Coll Cardiol 11:508-513 
17. Floras JS, Ponikowski P (2015) The sympathetic/parasympathetic imbalance in heart 
failure with reduced ejection fraction. Eur Heart J 36:1974–1982 
18. Böhm M, Perez A-C, Jhund PS, Reil JC, Komajda M, Zile MR, McKelvie RS, Anand IS, 
Massie BM, Carson PE, McMurray JJV, on behalf of the  I-Preserve Committees and 
Investigators (2014) Relationship between heart rate and mortality and morbidity in the 
irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). 
Eur J Heart Fail 16:778–787 
19. Kaye D, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD (1995) Adverse 
consequences of high sympathetic nervous activity in the failing human heart. J Am Coll 
Cardiol 26:1257-1263 
Page 15 of 24 
 
20. Greene SJ, Vaduganathan M, Wilcox JE, Harinstein ME, Maggioni AP, Subacius H, 
Zannad F, Konstam MA, Chioncel O, Yancy CW, Swedberg K, Butler J, Bonow RO, 
Gheorghiade M, on behalf of the EVEREST Trial Investigators (2013) The prognostic 
significance of heart rate in patients hospitalized for heart failure with reduced ejection 
fraction in sinus rhythm: Insights from the EVEREST (Efficacy of Vasopressin 
Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. J Am Coll Cardiol 
HF 1:488–496 
21. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, 
Tavazzi L, on behalf of the SHIFT Investigators (2010) Ivabradine and outcomes in 
chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet (376):875–
885 
22. Vazir A, Claggett B, Jhund P, Castagno D, Skali H, Yusuf S, Swedberg K, Granger CB, 
McMurray JJV, Pfeffer MA, Solomon SD (2015 ) Prognostic importance of temporal 
changes in resting heart rate in heart failure patients: an analysis of the CHARM 
program. Eur Heart J 36:669–675 
23. Bertomeu-González V, Núñez J, Núñez E, Cordero A, Fácila L, Ruiz-Granell R, Quiles J, 
Sanchis J, Bodí V, Miñana G, Bertomeu V, Llàcer A (2010) Heart rate in acute heart 
failure, lower is not always better. Int J Cardiol 145:592-593 
24. Rienstra M, Van Gelder IC, Van den Berg MP, Boomsma F, Hillege HL, Van Veldhuisen 
DJ (2006) A comparison of low versus high heart rate in patients with atrial fibrillation 
and advanced chronic heart failure: Effects on clinical profile, neurohormones and 
survival. Int J Cardiol 109:95 – 100 
25. Swedberg K, Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Shi H, Vincent M, 
John , Pitt B, for the EMPHASIS-HF Study Investigators (2012) Eplerenone and atrial 
fibrillation in mild systolic heart failure Results from the EMPHASIS-HF (Eplerenone in 
Page 16 of 24 
 
Mild Patients Hospitalization And SurvIval Study in Heart Failure) Study. J Am Coll 
Cardiol 59:1598–1603 
26. Ferreira JP, Rossignol P, Machu J-L, Sharma A, Girerd N, Anker SD, Cleland JG, 
Dickstein K, Filippatos G, Hillege HL, Lang CC, ter Maaten JM, Metra M, Ng L, 
Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Voors AA, Zannad F 
(2017) Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced 
ejection fraction: findings from BIOSTAT-CHF. Eur J Heart Fail 19:1284–1293 
27. Komajda M, Anker SD, Cowie MR, Filippatos GS, Mengelle B, Ponikowski P, Tavazzi 
L, on behalf of the QUALIFY Investigators (2016) Physicians’ adherence to guideline-
recommended medications in heart failure with reduced ejection fraction: data from the 
QUALIFY global survey. Eur J Heart Fail 18 (5):514-522 
28. Savarese G, Carrero J-J, Pitt B, Anker SD, Rosano GMC, Dahlström U, Lund LH (2018) 
Factors associated with underuse of mineralocorticoid receptor antagonists in heart 
failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish 
Heart Failure Registry. Eur J Heart Fail. doi:10.1002/ejhf.1182 
29. Banka G, Heidenreich PA, Fonarow GC (2013) Incremental cost-effectiveness of 
guideline-directed medical therapies for heart failure. J Am Coll Cardiol 61:1440–1446 
30. Rohde LE, Bertoldi EG, Goldraich L, Polanczyk CA (2013) Cost-effectiveness of heart 
failure therapies. Nat Rev Cardiol 10:338–354 
31. Bapoje SR, Bahia A, Hokanson JE, Peterson PN, Heidenreich PA, Lindenfeld J, Allen 
LA, Masoudi FA (2013) Effects of mineralocorticoid receptor antagonists on the risk of 
sudden cardiac death in patients with left ventricular systolic dysfunction: A meta-
analysis of randomized controlled trials. Circ Heart Fail 6:166-173 
32. Rossello X, Ariti C, Pocock SJ, Ferreira JP, Girerd N, McMurray JJV, van Veldhuisen 
DJ, Pitt B, Zannad F (2018) Impact of mineralocorticoid receptor antagonists on the risk 
Page 17 of 24 
 
of sudden cardiac death in patients with heart failure and left ventricular systolic 
dysfunction: an individual patient-level meta-analysis of three randomized-controlled 
trials. Clin Res Cardiol:doi: 10.1007/s00392-00018-01378-00390. [Epub ahead of print] 
33. Böhm M, Borer J, Ford I, Gonzalez-Juanatey JR, Komajda M, Lopez-Sendon J, Reil J-C, 
Swedberg K, Tavazzi L (2013) Heart rate at baseline influences the effect of ivabradine 
on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin 
Res Cardiol 102:11–22 
 
 
 
 
 
 
Page 18 of 24 
 
Legend to Figures 
 
Figure 1 
Kaplan-Meier plots of major cardiovascular outcomes according to heart rate. 
 
Figure 2 
Adjusted event rates and 95% CI by baseline heart rate categories on major cardiovascular 
outcomes. 
 
Figure 3 
Adjusted hazard ratio (eplerenone versus placebo) for all patients and by baseline heart rate 
categories for the primary endpoint, its components and all cause death. 
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Table 1. Baseline patient characteristics in the EMPHASIS-HF study according to baseline heart rate categories. 
 
   Heart Rate   
  <60 bpm 60-69 bpm 70-79 bpm 80+ bpm 
P-value1 
  (N=423) (N=792) (N=697) (N=824) 
Eplerenone, N(%) 197 (46.6) 401 (50.6) 360 (51.6) 405 (49.2) 0.58 
Age-years 69.3 (7.5) 68.8 (7.6) 68.9 (7.9) 68.0 (7.5) 0.006 
Male, N(%) 344 (81.3) 616 (77.8) 533 (76.5) 633 (76.8) 0.10 
Smoking, N(%)                 <0.001 
Never 173 (40.9) 334 (42.2) 324 (46.5) 391 (47.5)   
Current 38 (9.0) 83 (10.5) 74 (10.6) 98 (11.9)   
Ex 212 (50.1) 375 (47.3) 299 (42.9) 335 (40.7)   
Ethnicity, N(%)                 <0.001 
White 373 (88.2) 696 (87.9) 575 (82.5) 623 (75.6)   
Black 5 (1.2) 21 (2.7) 24 (3.4) 17 (2.1)   
Asian 30 (7.1) 53 (6.7) 72 (10.3) 161 (19.5)   
Other 15 (3.5) 22 (2.8) 26 (3.7) 23 (2.8)   
SBP-mmHg 125.8 (17.3) 124.4 (16.3) 123.9 (16.6) 123.2 (17.4) 0.009 
DBP-mmHg 73.4 (10.5) 73.6 (9.8) 74.8 (10.1) 76.1 (10.4) <0.001 
LVEF-% 26.6 (4.2) 26.1 (4.7) 26.2 (4.7) 25.8 (4.7) 0.02 
BMI-kg/m2 27.6 (4.7) 27.4 (4.4) 27.6 (4.9) 27.6 (5.4) 0.81 
Principal cause of heart failure, N(%)                 <0.001 
Ischaemic 309 (73.0) 578 (73.0) 469 (67.3) 530 (64.3)   
Non-Ischaemic 113 (26.7) 214 (27.0) 227 (32.6) 292 (35.4)   
Unknown 1 (0.2) 0 (0.0) 1 (0.1) 2 (0.2)   
Duration of HF-years 4.9 (5.6) 5.3 (6.1) 4.7 (5.7) 4.0 (5.4) <0.001 
Medical History, N(%)                   
Hospitalisation for heart failure 190 (44.9) 439 (55.4) 354 (50.8) 456 (55.3) 0.02 
Hypertension 289 (68.3) 540 (68.2) 455 (65.3) 535 (64.9) 0.11 
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Angina 205 (48.5) 393 (49.6) 300 (43.0) 291 (35.3) <0.001 
Previous MI 246 (58.2) 450 (56.8) 340 (48.8) 345 (41.9) <0.001 
PCI 113 (26.7) 195 (24.6) 140 (20.1) 148 (18.0) <0.001 
CABG 84 (19.9) 185 (23.4) 122 (17.5) 125 (15.2) <0.001 
Atrial fibrillation or flutter 101 (23.9) 201 (25.4) 210 (30.1) 332 (40.3) <0.001 
Any Pacemaker/CRT pacing 31 (7.3) 149 (18.8) 129 (18.5) 91 (11.1) 0.97 
Left Bundle Branch Block 101 (26.4) 169 (27.0) 158 (28.7) 180 (25.1) 0.65 
Right Bundle Branch Block 27 (7.0) 45 (7.2) 45 (8.2) 51 (7.1) 0.89 
Diabetes 99 (23.4) 231 (29.2) 222 (31.9) 307 (37.3) <0.001 
Stroke 54 (12.8) 75 (9.5) 59 (8.5) 74 (9.0) 0.06 
ICD 59 (13.9) 139 (17.6) 94 (13.5) 70 (8.5) <0.001 
Haemoglobin-g/dl 13.7 (1.5) 13.9 (1.5) 13.8 (1.6) 13.8 (1.7) 0.90 
Creatinine-mg/dl 1.2 (0.3) 1.1 (0.3) 1.1 (0.3) 1.1 (0.3) 0.02 
eGFR-ml/min/1.73m2 69.7 (20.5) 70.9 (21.8) 70.5 (22.9) 71.5 (21.6) 0.25 
eGFR<60-N.(%) 146 (34.7) 265 (33.6) 247 (35.5) 248 (30.2) 0.13 
Potassium-mmol/l 4.4 (0.4) 4.3 (0.4) 4.3 (0.4) 4.3 (0.5) 0.006 
Medication at randomisation visit, N(%)                   
Diuretic 344 (81.3) 649 (81.9) 576 (82.6) 732 (88.8) <0.001 
ACE inhibitor 323 (76.4) 610 (77.0) 543 (77.9) 626 (76.0) 0.84 
ARB 82 (19.4) 150 (18.9) 136 (19.5) 152 (18.4) 0.74 
ACE and/or ARB 393 (92.9) 732 (92.4) 652 (93.5) 755 (91.6) 0.51 
Beta-blocker 383 (90.5) 706 (89.1) 604 (86.7) 659 (80.0) <0.001 
Calcium Channel Blocker 49 (11.6) 82 (10.4) 72 (10.3) 73 (8.9) 0.14 
Antiarrhythmic drug 77 (18.2) 123 (15.5) 85 (12.2) 97 (11.8) <0.001 
Antithrombotic drug 378 (89.4) 703 (88.8) 608 (87.2) 703 (85.3) 0.02 
Digitalis glycosides 73 (17.3) 154 (19.4) 197 (28.3) 310 (37.6) <0.001 
Lipid-lowering agent 297 (70.2) 517 (65.3) 418 (60.0) 457 (55.5) <0.001 
Numbers are mean (SD) unless otherwise specified; 1 p-value from test for trend 
 
 
Page 21 of 24 
 
Table 2: Number of events, event rate and hazard ratios by baseline heart rate categories for the primary endpoint, its component events and 
all cause death. 
 
Study Endpoint N. Events (Rate1) HR (95% CI) P-value2 Adj HR3 (95% CI) p-value2 
Primary Endpoint             
<60 423 96 (11.4) 1.09 (0.85,1.41)   1.15 (0.89,1.49)   
60-69 792 162 (10.5) Reference   Reference   
70-79 697 163 (12.0) 1.15 (0.93,1.43)   1.16 (0.93,1.44)   
80+ 824 258 (17.2) 1.64 (1.35,1.99) <0.001 1.61 (1.31,1.99) <0.001 
Cardiovascular Death             
<60 423 56 (6.2) 1.16 (0.83,1.61)   1.16 (0.82,1.63)   
60-69 792 90 (5.4) Reference   Reference   
70-79 697 94 (6.4) 1.18 (0.88,1.58)   1.15 (0.86,1.55)   
80+ 824 152 (9.0) 1.66 (1.28,2.16) <0.001 1.57 (1.18,2.08) 0.009 
Hospitalization for Heart Failure             
<60 423 59 (7.0) 0.93 (0.68,1.27)   1.04 (0.75,1.43)   
60-69 792 117 (7.5) Reference   Reference   
70-79 697 110 (8.1) 1.08 (0.83,1.40)   1.07 (0.82,1.39)   
80+ 824 177 (11.8) 1.55 (1.23,1.96) <0.001 1.50 (1.16,1.93) 0.006 
All Cause Mortality             
<60 423 63 (7.0) 1.05 (0.77,1.43)   1.06 (0.77,1.46)   
60-69 792 111 (6.7) Reference   Reference   
70-79 697 107 (7.2) 1.09 (0.83,1.42)   1.08 (0.82,1.42)   
80+ 824 176 (10.4) 1.56 (1.23,1.97) <0.001 1.53 (1.18,1.98) 0.003 
1 Rate per 100 patient years;  2 p-value from test for trend; 3HR was adjusted for randomized treatment, age, sex, race, SBP, BMI, LVEF, 
serum creatinine, cause of HF, duration of HF, DM, AF, hypertension, prior hospitalization for HF, stroke, ICD/CRT, ACE inhibitors/ARBs, 
beta-blocker, CCB, digoxin, antiarrhythmic drugs. 
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Figure 1. Kaplan-Meier plots of major cardiovascular outcomes according to heart rate. 
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Figure 2. Adjusted event rates and 95% CI by baseline heart rate categories on major 
cardiovascular outcomes. 
 
 
Note: Rates are estimated from a Poisson model and adjusted for: age, sex, race, SBP, BMI, LVEF, 
serum creatinine, cause of HF, duration of HF, DM, AF, hypertension, prior hospitalization for HF, 
stroke, ICD/CRT, ACE inhibitors/ARBs, beta-blocker, beta-blocker dose, CCB, digoxin, antiarrhythmic 
drugs. 
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Figure 3. Adjusted hazard ratio (eplerenone versus placebo) for all patients and by baseline 
heart rate categories on major cardiovascular outcomes.   
 
 
 
 
Note: Hazard ratio is adjusted for: age, sex, race, SBP, BMI, LVEF, serum creatinine, cause of HF, 
duration of HF, DM, AF, hypertension, prior hospitalization for HF, stroke, ICD/CRT, ACE 
inhibitors/ARBs, beta-blocker, beta-blocker dose, CCB, digoxin, antiarrhythmic drugs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
